Erythropoietin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 07.10.2022

Dieser Artikel auf Deutsch

Synonym(s)

EPO; Epoetin

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

cytokine, 85% of which is produced in the tubular and juxtatubular endothelial capillary cells and interstitial cells of the kidney as a function of O2 partial pressure. Hepatocytes and Kupffer star cells are another place of formation.

Pharmacodynamics (Effect)This section has been translated automatically.

Stimulation of erythropoiesis in the bone marrow. Expansion of the quantity of immature progenitor cells of the BFU-E ("burst forming unit") type, which are transferred in the compartment of more mature determinant progenitor cells CFU-E ("erythroid colony forming unit") and accelerate their maturation. Prevention of apoptosis so that more erythrocytes can mature.

IndicationThis section has been translated automatically.

Renal anaemia, autologous blood transfusions before elective surgery, severe anaemia.

Notice. Erythropoietin should be used with caution in patients with high blood pressure, ischemic vascular diseases and known epilepsy!

Limited indicationThis section has been translated automatically.

Malignancies, epilepsy, thrombocytosis, chronic Liver failure.

Dosage and method of useThis section has been translated automatically.

  • Renal anaemia: 50 IU/kg bw 3 times/week, possibly increased by 25 IU/kg bw 3 times/week until a haematocrit of 30-35% is reached. Maximum dose 600 IU/kg bw/week.
  • Other indications: 150 IU/kg bw s.c. 3 times/week. Dose adjustment 4 weeks after the start of therapy:
    • Hb > 1 g/100 ml or reticulocytes > 40.000/μl: maintenance of the dose.
    • Hb < 1 g/100 ml or reticulocytes < 40.000/μl: dose increase to 3 times 300 IU/kg bw/week, after 4 weeks renewed control. In the absence of an increase in Hb to > 1 g/100 ml or reticulocytes to > 40,000/μl therapy discontinuation, since therapy response is unlikely.

Notice! In oncological patients the increase in Hb should not exceed 2 g/100 ml/month or Hb values > 14 g/100 ml should be avoided!

Notice! Patients undergoing platinum-containing chemotherapy have a significantly increased risk of high blood pressure. Patients who participate in an autologous blood donation program should undergo volume replacement to reduce the risk of thromboembolic and vascular disease!

Undesirable effectsThis section has been translated automatically.

Hypertension, occlusion of arterio-venous shunts, allergic reactions, epileptic seizures, flu-like symptoms, dizziness, headache, pruritus, hypertensive encephalopathy, myocardial infarction.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, hard-to-control hypertension.

PreparationsThis section has been translated automatically.

Erypo, NeoRecormon

Authors

Last updated on: 07.10.2022